Oncofetal Proteins and Cancer-Testis Antigens

Oncofetal proteins and cancer-testis antigens (CTAs) represent a diverse group of proteins that are normally expressed during fetal development or in immune-privileged sites like the testis, but are aberrantly re-expressed in various cancers. This re-expression is often linked to a cellular 'regression' to a more primitive, embryonic state, a hallmark of malignancy. These proteins can contribute to tumor initiation, progression, and therapy resistance by promoting cell proliferation, invasion, and stemness. Examples include alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA), which are used as tumor markers, and CTAs like NY-ESO-1 and MAGE-A3. Due to their restricted expression in normal adult tissues and their presence in cancer, these proteins are considered promising targets for cancer immunotherapy, including vaccines and T-cell therapies. Strategies to enhance their expression, such as using epigenetic modifiers, are also being explored to improve therapeutic outcomes.

Other names

Retired proteins re-expressed in cancerOncofetal antigensDevelopmental antigens re-expressed in cancerTumor-associated developmental proteins

Oncofetal proteins and cancer-testis antigens (CTAs) are typically involved in embryonic development or germ cell function and are silenced in healthy adult somatic tissues. Their re-expression in cancer cells contributes to tumorigenesis by promoting cell proliferation, invasion, stemness, and resistance to therapy. As therapeutic targets, drugs aim to induce anti-tumor immune responses by presenting these aberrantly expressed proteins to the immune system, often through cancer vaccines or T-cell therapies. Epigenetic modifiers, such as DNA methyltransferase inhibitors like decitabine, can enhance the expression of these antigens, thereby increasing their immunogenicity and making cancer cells more susceptible to immune-mediated destruction.